What is it about?
Magnitude of "bad" cholesterol (LDL-C) reduction is important for patients with prior heart attacks, prior strokes, or symptoms of blood vessel narrowings in the legs. This paper compares the effect of different subcutaneous doses of evolocumab (70 mg or 140 mg every 2 weeks; 280 mg and 420 mg monthly) on LDL-C and other lipids.
Featured Image
Why is it important?
These data show that 140 mg every 2 weeks and 420 mg monthly of evolocumab resulted in a 63% average reduction in LDL-C, which was about 20% greater than 70 mg every 2 weeks and about 7% greater than 280 mg monthly. Additionally, the 140 mg and 420 mg doses had about 10% less peak-trough variability over the dosing intervals.
Perspectives
Absolute reduction in "bad" cholesterol matters for patients with prior heart attacks, prior strokes, or symptoms for blood vessel narrowings in their legs. Physician decisions on the doses of lipid-lowering therapies matter when it comes to reducing the risk of future heart attacks or strokes. It is critical to get it right.
Scott Wasserman
Amgen Inc
Read the Original
This page is a summary of: Comparison of LDL-C Reduction Using Different Evolocumab Doses and Intervals, Journal of Cardiovascular Pharmacology and Therapeutics, May 2018, SAGE Publications,
DOI: 10.1177/1074248418774043.
You can read the full text:
Contributors
The following have contributed to this page
